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Oral Presentations S225alloreactive responses, mixed lymphocyte reactions (MLR) were
performed (n 5 6). High-dose, activated cyclophosphamide (mafos-
famide) given 3 days after the start of MLR caused increases in Fr
I-III at 7 days (Fr II, p\0.0001; Fr III, p 5 0.0002), while cyclo-
sporine-treated cells had similar to lower levels of these fractions
compared with controls. The addition of mafosfamide at day 3 to
cyclosporine-cultured cells in MLR caused similar increases in Fr
I and III as seen with mafosfamide alone, but the Fr II increase
was no longer significant. In summary, T cell reconstitution in pa-
tients treated with PT/Cy differs from that seen with CNI-based
GVHD prophylaxis. For patients treated with PT/Cy who still de-
velop aGVHD, relative expansion of Tregs may be a critical com-
pensatory mechanism accounting for the remarkably low incidence
of chronic GVHD seen in these patients.60
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Alloreactivity after transplantation is associated with profound im-
mune suppression and consequent opportunistic infection results in
high morbidity and mortality. This immune suppression is most
dramatic during graft–versus–host disease (GVHD) after bone
marrow transplantation (BMT) where an inflammatory cytokine
storm dominates. We used the B6 (I-Ab/I-E-/-)/ BALB/c (I-Ad/
I-Ed) BMT model to track antigen specific responses induced by
donor APC. Bone marrow grafts were either T cell depleted
(non-GVHD) or replete (GVHD) and derived from wild-type or
CD11c.OVA transgenic (Tg) donors. We determined the extent
of antigen presentation by quantifying CFSE dilution of adoptively
transferred TEa Tg T cells (which respond to host I-Ed presented
in donor I-Ab) and OT-II Tg T cells (which respond to OVA-de-
rived peptide). GVHD induced a marked defect in antigen presen-
tation of both alloantigen and nominal antigens. By utilizing
CD11c.DTR Tg grafts and DC-depletion with diphtheria toxin
we demonstrated that conventional DC (cDC) were the critical do-
nor cell presenting alloantigen during GVHD. Surprisingly, num-
ber, phenotype and phagocytic/proteolytic function of these cells
were all equivalent in the GVHD and non-GVHD settings. How-
ever, cDC from mice with GVHD failed to present OVA Ag within
MHC II to OT-II T cells, confirming a DC specific defect during
GVHD. In contrast, both classical and cross presentation within
MHC class I remained intact. Analysis of cDC subsets revealed
that the CD8neg donor cDC were the critical cell population for
class-II mediated Ag presentation and that this specific sub-popula-
tion was defective during GVHD. This defect is two-fold, and is
caused by both a functional impairment in class II presentation
in the CD4negCD8neg cDC population, and a concurrent failure
of development in the CD4+CD8neg population. Importantly, the
functional defect in antigen processing within MHC class II can
be reversed by TNF inhibition or the adoptive transfer of donor
cDC generated in the absence of inflammation.61
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CenterBackground: Elucidation of immune tolerance-associated biomarkers
may facilitate personalizedmanagement of immune suppression (IS) fol-
lowing allogeneic hematopoietic cell transplantation (HCT).
Methods: We have performed an analysis of differential gene ex-
pression between tolerant, non-tolerant, and healthy control sub-
jects. Tolerant cases (n 5 17) were HCT recipients off IS for at
least 6 months without any manifestations of acute or chronic graft
vs. host disease (GVHD). Non-tolerant comparators (n 5 16) were
matched for age (+/- 5 years) and time from date of HCT (+/- 6
months), but failed to discontinue IS due to GVHD. Published gene
expression data from healthy volunteer subjects (n5 9) served as con-
trol. Clinical data gathered on all tolerant (TOL) and non-Tolerant
(non-TOL) cases included patient demographic and HCT informa-
tion, comprehensive review of acute and chronic GVHD activity,
and history of IS drug therapy. From freshly obtained peripheral blood
samples, two analyses were performed: First, from total peripheral
bloodmononuclear cells (PBMC), cell populations were characterized
by surface phenotype with flow cytometry. Second, RNA was ex-
tracted from fresh PBMC to serve as themRNA source for microarray
analysis using the Affymetrix Human U133 plus 2.0 array.
Results: Demographic and transplantation variables did not signif-
icantly differ between groups. We did not detect significant differ-
ences in cell composition (ab T cells, gd T cells, regulatory T
cells, NKT cells, NK cells, B cells, monocytes, type 1 and type 2 den-
dritic cells) betweenTOLand non-TOLgroups.We first conducted
a two group (TOL vs. non-TOL) comparison of gene expression.
SAM analysis with 300 permutations, $ 1.5-fold change, and 10%
false discovery rate identified 231 genes up- and 412 down-regulated
in Tol vs. non-Tol groups. Pathway analysis (MetaCore byGeneGo)
mapped involved genes to immune response pathways involving T
cell (TCR receptor signaling, NF-AT) and NK cell (DAP12,
NKG2D, CD16) signaling. Construction of a 3-way (TOL vs.
non-TOL vs. control) classifier resulted in a weighted accuracy of
88% for leave 10% out cross-validation.
Conclusion: These data demonstrate differential gene expression
among tolerant HCT recipients distinct from both non-tolerant
and control subjects, and support a classifier that can accurately iden-
tify the tolerant phenotype. Confirmation of these results will re-
quire a prospective trial of IS discontinuation.62
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Background: T-cell function is defective after allogeneic stem cell
transplantation (ASCT). This has a significant clinical impact by in-
creasing patients’ susceptibility to infections, thus reducing survival.
One way to assess thymic output of T-cells is by measuring the level
of T-cell receptor excision circles (TRECs).
Methods:This retrospective study involved 210 patients with hema-
tological malignancies. TREC levels in separated T-cells were mea-
sured at 6 time-points during the first 24-months after ASCT, using
quantitative real-time PCR.
Results:The use of bonemarrow grafts rather than peripheral blood
stem cell grafts showed a significant correlation with higher TREC
levels .6 months after ASCT (p\0.001). Treatment with anti-thy-
mocyte globulin was correlated with lower TREC levels#6 months
post-ASCT (p\0.001). The group of patients with TREC levels
above median 3 months post-ASCT had a superior overall survival;
80% vs. 56% (p5 0.002), and lower transplantation-related mortal-
ity; 7% vs. 21% (p 5 0.01).
Conclusion: These results give further evidence that thymic func-
tion has an important role in the reconstitution of the T-cell pool af-
ter ASCT. We have also shown that factors related to the ASCT
treatment itself, such as graft source and in-vivo T-cell depletion,
may have a significant effect on TREC levels, and can subsequently
affect outcome. These findings also support the use of TREC mea-
surement as part of the standard repertoire of immunological mon-
itoring after ASCT.
